帕博利珠单抗单药治疗对比化疗用于既往未经治疗的晚期非小细胞肺癌的成本效益分析

数据集获取（Figshare）

• 源站标题：Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
• DOI：10.6084/m9.figshare.12382874.v1
• 发布日期：2020-05-28
• 文件数：4 个
• 文件总体积：221.62 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_pembrolizumab_monotherapy_versus_chemotherapy_for_previously_untreated_advanced_non-small_cell_lung_cancer/12382874

命令行下载

curl -L -o "ijme_a_1775620_sm8300.docx" "https://ndownloader.figshare.com/files/22817903"
curl -L -o "ijme_a_1775620_sm8299.docx" "https://ndownloader.figshare.com/files/22817906"
curl -L -o "ijme_a_1775620_sm8298.tif" "https://ndownloader.figshare.com/files/22817909"
curl -L -o "ijme_a_1775620_sm8297.tif" "https://ndownloader.figshare.com/files/22817912"

文件清单

• ijme_a_1775620_sm8300.docx（16.11 KB）
• ijme_a_1775620_sm8299.docx（21.09 KB）
• ijme_a_1775620_sm8298.tif（92.08 KB）
• ijme_a_1775620_sm8297.tif（92.34 KB）

文件总体积 221.62 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective: To assess the cost-effectiveness of pembrolizumab monotherapy compared with standard chemotherapy for the treatment of advanced non-small cell lung cancer (NSCLC) in previously untreated adults who have a high programmed death ligand 1 (PD-L1) tumor proportion score of 50% or greater in Singapore.
Materials and methods: A partitioned-survival analysis model was developed from a healthcare system’s perspective that extrapolated clinical and economic outcomes of first-line pembrolizumab (maximum treatment duration of 2 years) versus platinum doublet chemotherapy over a 10-year time horizon for patients with advanced NSCLC. The model consisted of three health states: alive with no progression, alive with progression, and dead. Key clinical inputs were based on Kaplan-Meier survival curves from the interim (median follow-up = 11.2 months) and updated analysis (median follow-up = 25.2 months) of the KEYNOTE-024 randomized controlled trial. Local cost data were applied. Utilities were derived from published international estimates. Both one-way and multivariate probabilistic sensitivity analyses (PSA) were conducted to identify key drivers of the results.
Results: Using the results from the updated analysis of KEYNOTE-024, patients treated with pembrolizumab experienced more quality adjusted life-years (QALYs), but incurred higher costs compared to chemotherapy over a 10-year time horizon (pembrolizumab: 1.9983 QALYs, SGD215,761; chemotherapy: 1.1317 QALYs, SGD70,444). The base-case incremental cost-effectiveness ratio (ICER) was SGD167,692 per QALY gained. One-way sensitivity analysis showed the ICER was most sensitive to the cost of pembrolizumab, followed by the time horizon. Multivariate PSA indicated that pembrolizumab had 0% probability of being cost-effective at a hypothetical willingness-to-pay threshold of SGD100,000 per QALY gained.
Conclusion: While pembrolizumab is superior to standard chemotherapy in improving overall survival and progression-free survival, results suggest that it is unlikely to be cost-effective at its current price in Singapore. Factors including clinical effectiveness, safety, and budget impact should also be considered w

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.12382874.v1（source: https://tandf.figshare.com/articles/dataset/Cost-effectiveness_analysis_of_pembrolizumab_monotherapy_versus_chemotherapy_for_previously_untreated_advanced_non-small_cell_lung_cancer/12382874）。